I would be tempted to raise the buyout probability

I would be tempted to raise the buyout probability percentage. One of the points made in the article below is that splitting out indications for a platform molecule is problematic, increases the risk for the partner, and consequently is rarely done. That said, the word “partnership” has been used numerous times by Scott Kelly and others, so clearly I am just drawing inferences and guessing. Another point in the article, much discussion can center around 1+1=3, “how can we work together to increase value, make the pie bigger.” Cytodyn has a very small team, granted there are some superheroes there like Recknor, but my sense is collaboration for that kind of math implies a much deeper bench. With enough money and no “salary cap” you can buy a great bench but the extant bench is limited. Ohm20 has done a deep dive and I am sure can attest some (most if not all) of the indications require some complex, thoughtful and time consuming work to arrive at a well engineered trial protocol. Stroke had been mentioned as a potential near term target for example; what may appear straightforward initially gets complex in a hurry when trying to achieve clarity in outcome: hemorrhagic stroke vs vessel occlusion, last known well, door to needle time, CT etc. Time is brain and many of the time points that impact outcomes for stroke are systems of care related and have to be factored into the study. My point related to your question, do you take your biggest problem and skip it. Does somebody already have a deep bench in place, maybe their essential need is for an architect who understands the mechanism of action intimately and can be like ATC directing traffic.

So, BP will need to weigh in, but my myopic read looks like B (buyout) comes before P (partnership). Another point to lend credence, whoever the company is in discussions with, when they really grasp that this is the penultimate platform molecule, the Swiss Army knife of drugs with massive markets, I expect greed to kick in, they will want it all.

https://www.nature.com/articles/d43747-020-00810-0